Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for FortiCore devices in 2014. The company gained an additional FDA 510(k) in 1Q18 for FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core. These devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF).
Source: Nanovis
Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for...
Nanovis completed a US $5.5MM funding round to support sales and distribution of its FortiCore® interbody fusion devices.
Investors in the round included Elevate Ventures, 1st Source Capital Corporation, Purdue’s Foundry Investment Fund, Commenda Capital and Ellipsis Ventures.
Nanovis received initial FDA 510(k) marketing clearance for FortiCore devices in 2014. The company gained an additional FDA 510(k) in 1Q18 for FortiCore® interbody fusion devices that feature a Nanosurface-enhanced porous titanium scaffold, intermolded with a PEEK core. These devices are intended for use in transforaminal and anterior lumbar interbody fusion procedures (TLIF and ALIF).
Source: Nanovis
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.